Levicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026

Levicept Ltd presented Phase II clinical trial data for LEVI-04, a first-in-class neurotrophin-3 inhibitor for osteoarthritis treatment, at the EULAR conference in London. The study of 518 patients demonstrated significant dose-dependent reductions in bone marrow lesions, clinically meaningful improvements in pain and function comparable to NSAIDs, and a differentiated safety profile compared to anti-NGF therapies.